milatuzumab
Sponsors
Gilead Sciences, Kaplan Medical Center, Beth Christian
Conditions
Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)Chronic Lymphocytic LymphomaChronic Myelogenous Leukemia (CML)GVHD (Acute or Chronic)Lupus Erythematosus, CutaneousLupus Erythematosus, Discoid
Phase 1
Phase I/II Study of hLL1 in Multiple Myeloma
CompletedNCT00421525
Start: 2007-01-31End: 2009-06-30Updated: 2021-08-16
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
CompletedNCT00603668
Start: 2008-08-31End: 2013-02-28Updated: 2021-08-16
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
NCT00868478
Start: 2009-04-30End: 2012-04-30Target: 15Updated: 2010-06-02
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
CompletedNCT00989586
Start: 2009-09-30End: 2015-09-30Updated: 2017-02-06
Phase I Study of Milatuzumab for Graft Versus Host Disease
TerminatedNCT01663766
Start: 2013-12-31End: 2015-03-31Updated: 2021-08-19
Phase Ib Study of SC Milatuzumab in SLE
CompletedNCT01845740
Start: 2007-01-31End: 2009-06-30Updated: 2021-08-19